Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer

Given the established individual activity of docetaxel and ifosfamide in anthracycline pretreated advanced breast cancer, the present phase I–II study aimed to define the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), and activity of the docetaxel–ifosfamide combination in this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosmas, C, Tsavaris, N, Malamos, N, Stavroyianni, N, Gregoriou, A, Rokana, S, Polyzos, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747562/
https://www.ncbi.nlm.nih.gov/pubmed/12698179
http://dx.doi.org/10.1038/sj.bjc.6600887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747562/
https://www.ncbi.nlm.nih.gov/pubmed/12698179
http://dx.doi.org/10.1038/sj.bjc.6600887

Ejemplares similares